Hyperbaric oxygen therapy as an immunomodulatory intervention in COVID-19-induced ARDS: Exploring clinical outcomes and transcriptomic signatures in a randomised controlled trial.
- DOI
- 10.1016/j.pupt.2024.102330
- Published
- 2024 Dec
- Container
- Pulmonary pharmacology & therapeutics
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.pupt.2024.102330,
title = {Hyperbaric oxygen therapy as an immunomodulatory intervention in COVID-19-induced ARDS: Exploring clinical outcomes and transcriptomic signatures in a randomised controlled trial.},
author = {Kjellberg A and Zhao A and Lussier A and Hassler A and Al-Ezerjawi S and Boström E and Catrina SB and Bergman P and Rodriguez-Wallberg KA and Lindholm P},
year = {2024},
journal = {Pulmonary pharmacology \& therapeutics},
doi = {10.1016/j.pupt.2024.102330},
url = {https://doi.org/10.1016/j.pupt.2024.102330}
}RIS
TY - JOUR TI - Hyperbaric oxygen therapy as an immunomodulatory intervention in COVID-19-induced ARDS: Exploring clinical outcomes and transcriptomic signatures in a randomised controlled trial. AU - Kjellberg A AU - Zhao A AU - Lussier A AU - Hassler A AU - Al-Ezerjawi S AU - Boström E AU - Catrina SB AU - Bergman P AU - Rodriguez-Wallberg KA AU - Lindholm P PY - 2024 JO - Pulmonary pharmacology & therapeutics DO - 10.1016/j.pupt.2024.102330 UR - https://doi.org/10.1016/j.pupt.2024.102330 ER -
APA
A, K., A, Z., A, L., A, H., S, A., E, B., SB, C., P, B., KA, R., & P, L. (2024). Hyperbaric oxygen therapy as an immunomodulatory intervention in COVID-19-induced ARDS: Exploring clinical outcomes and transcriptomic signatures in a randomised controlled trial.. Pulmonary pharmacology & therapeutics. https://doi.org/10.1016/j.pupt.2024.102330
Source records
- pubmed · retrieved 2026-09-26T13:29:46.977Z